Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2007002512) NEUROPROTECTIVE EFFECTIVE COMPOUND
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/002512 International Application No.: PCT/US2006/024656
Publication Date: 04.01.2007 International Filing Date: 23.06.2006
IPC:
A61K 48/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Applicants:
TISSUEGENE, INC. [US/US]; 209 Perry Parkway Suite 13 Gaithersburg, MD 20877, US (AllExceptUS)
LEE, Kwan, Hee [KR/US]; US (UsOnly)
LEE, Duk, Keun [KR/US]; US (UsOnly)
YI, Youngsuk [KR/US]; US (UsOnly)
NOH, Moon, Jong [KR/US]; US (UsOnly)
KIM, Hyoung, Chun [KR/KR]; KR (UsOnly)
Inventors:
LEE, Kwan, Hee; US
LEE, Duk, Keun; US
YI, Youngsuk; US
NOH, Moon, Jong; US
KIM, Hyoung, Chun; KR
Agent:
KIM, Joseph, Hyosuk; JHK Law P.O. Box 1078 La Canada, CA 91012-1078, US
Priority Data:
60/595,34223.06.2005US
Title (EN) NEUROPROTECTIVE EFFECTIVE COMPOUND
(FR) COMPOSE NEUROPROTECTEUR EFFICACE
Abstract:
(EN) The present application discloses a method of preventing degeneration of nerve, which includes: a) generating a recombinant viral or plasmid vector comprising a DNA sequence encoding a member of a transforming growth factor superfamily or neurotrophic factor proteins operatively linked to a promoter; b) transfecting in vitro a population o cultured cells with the recombinant vector, resulting in a population of the cultured cells; and c) transplanting the transfected cells to an area near an injured nerve, such that expression of the DNA sequence within the area near the injured nerve causes prevention o degeneration of the nerve.
(FR) L'invention concerne un procédé destiné à la prévention de la dégénérescence des nerfs, procédé comprenant les étapes suivantes : a) génération d'un vecteur viral ou plasmide recombinant comprenant une séquence ADN codant un élément d'une superfamille de croissance transformant ou des protéines d'un facteur neurotrophique liées coopérantes à un promoteur ; b) transfection in vitro d'une population de cellules cultivées avec le vecteur recombinant, conduisant à l'obtention d'une population de cellules cultivées ; et c) transplantation des cellules transfectées en une aire voisine du nerf lésé, de sorte que l'expression de la séquence ADN dans ladite aire voisine du nerf lésé entraîne la prévention de la dégénérescence du nerf.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
KR1020080038310KR1020100074340EP1904113JP2009506982CN101232904CA2613551
JP2014088425KR1020130101595KR1020140132010ES2562243KR1020160021458DK1904113
CN106177996AU2006261889AU2010257453IN10145/DELNP/2007KR1020180057737